Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to 2415.68%.

  • Orchestra BioMed Holdings' EBITDA Margin fell 8650200.0% to 2415.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 2666.93%, marking a year-over-year decrease of 4942000.0%. This contributed to the annual value of 2310.92% for FY2024, which is 5311300.0% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its EBITDA Margin stood at 2415.68% for Q3 2025, which was down 8650200.0% from 2318.66% recorded in Q2 2025.
  • Orchestra BioMed Holdings' EBITDA Margin's 5-year high stood at 661.55% during Q1 2022, with a 5-year trough of 6403.56% in Q4 2024.
  • For the 4-year period, Orchestra BioMed Holdings' EBITDA Margin averaged around 2251.39%, with its median value being 2055.91% (2024).
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -39821200bps in 2023, then surged by 16228500bps in 2024.
  • Orchestra BioMed Holdings' EBITDA Margin (Quarter) stood at 884.68% in 2022, then crashed by -450bps to 4866.79% in 2023, then crashed by -32bps to 6403.56% in 2024, then skyrocketed by 62bps to 2415.68% in 2025.
  • Its last three reported values are 2415.68% in Q3 2025, 2318.66% for Q2 2025, and 2162.44% during Q1 2025.